UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of September 2026
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720,
333-207933, 333-215983,
333-222891, 333-233267
and 333-265866.
The following exhibit is attached:
| 99.1 |
|
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 10, 2026 |
KAMADA LTD. |
| |
|
| |
By: |
/s/ Nir Livneh |
| |
|
Nir Livneh |
| |
|
Vice President General Counsel and
Corporate Secretary |
EXHIBIT INDEX
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1 |
|
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference |
Exhibit 99.1
Kamada to Present at the
H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and Hoboken, NJ, – September
10, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products
indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief
Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte
New York Palace Hotel.
Mr. London is scheduled to present at the conference,
on Tuesday, September 15, 2026, at 2:30 p.m. Eastern Time. In addition to the presentation, Mr. London will be available for one-on-one
investor meetings throughout the conference. Investors that are interested in arranging a meeting should contact their H.C. Wainwright
representative.
A live webcast and audio archive of the event
may be accessed here
(the full link appears below as well) and through the investor relations section of Kamada’s website at https://www.kamada.com/events-presentations/.
The recording replay will be available for 30 days.
Link to webcast: https://journey.ct.events/view/e756f52e-3889-4b68-aca5-aaf0b71df91d
About Kamada
Kamada Ltd. (the “Company”) is a global
biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling
shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving
profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment
in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived
products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based
anti-snake venom products. Second, distribution of third-parties pharmaceutical products in Israel & the MENA region through in-licensing
partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations
to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing
demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States,
in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing
and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its
financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing,
research and development expertise to advance the development and commercialization of additional product candidates, targeting areas
of significant unmet medical need.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
